Pharmaceuticals turnover in the six months was £8,465 million, up 3% AER, 1% CER. Respiratory sales were up 21% AER, 17% CER, to £1,383 million, on growth of Trelegy Ellipta and Nucala. HIV sales were up 4% AER, 1% CER, to £2,330 million, with growth in Juluca and Dovato partly offset by a decline in Triumeq. Sales of Established Pharmaceuticals declined 6% AER, 7% CER to £4,380 million including the impact of loss of exclusivity of Advair. In the US, sales grew 1% AER but declined 5% CER. Continued growth of Nucala, Trelegy Ellipta and Benlysta was offset by the decline in Established Products including the loss of exclusivity of Advair and in Relvar/Breo Ellipta, impacted by genericisation of the ICS/LABA market. In Europe, sales grew 1% AER, 1% CER, with strong growth in Respiratory partly offset by a decline in Established Pharmaceuticals. International grew 6% AER, 6% CER, with growth in all therapy areas. Respiratory Total Respiratory sales were up 21% AER, 17% CER, with strong growth in all regions. Ellipta product sales grew 16% AER, 12% CER, with Europe up 28% AER, 29% CER and International up 32% AER, 31% CER on Trelegy Ellipta and Relvar/Breo Ellipta growth. Nucala was up 45% AER, 45% CER in Europe and 55% AER, 52% CER in International. In the US, Trelegy Ellipta and Nucala growth offset the decline in Relvar/Breo Ellipta on post-generic ICS/LABA price pressure. Sales of Nucala were £347 million in the six months and grew 42% AER, 37% CER, continuing to benefit from the global rollout of the product. US sales of Nucala grew 37% AER, 30% CER to £202 million. Sales of Ellipta products were up 16% AER, 12% CER to £1,036 million driven by growth in Europe and International. In the US, sales grew 6% AER but were flat at CER, reflecting continued competitive pricing pressures for ICS/LABA products post generic Advair. In Europe, sales grew 28% AER, 29% CER, and in International by 32% AER, 31% CER. Sales of Trelegy Ellipta, our new once daily closed triple product, contributed £207 million globally in the six months, continuing to benefit from the expanded US label. Relvar/Breo Ellipta sales were down 9% AER, 11% CER. This was driven by the US decline of 33% AER, 37% CER, impacted by US competitive pricing pressures and the impact of generic Advair on the US ICS/LABA market. In Europe and International, Relvar/Breo Ellipta continued to grow, up 11% AER, 12% CER, and 22% CER, 20% AER, respectively. HIV HIV sales grew 4% AER, 1% CER to £2,330 million in the six months to June. The dolutegravir franchise grew 7% AER, 3% CER, delivering sales of £2,214 million in the six months. The remaining portfolio with sales of £116 million, 5% of total HIV sales, declined 28% AER, 28% CER and reduced the overall growth of total HIV by 3% AER, 2% CER in the six months to June. Sales of dolutegravir products were £2,214 million in the six months, with Triumeq and Tivicay delivering sales of £1,260 million and £795 million, respectively. The two-drug regimens Juluca and Dovato delivered sales of £159 million in the six months to June. The combined growth of the two-drug regimens offset the decline in the three-drug regimen, Triumeq, as the business transitions to the new portfolio. In the US, the second two-drug regimen, Dovato, was launched in April 2019, which, combined with Juluca, delivered sales of £136 million. Total dolutegravir sales grew 4% AER but declined 1% CER reflecting the share decline in Tivicay and Triumeq, partly offset by the share gain on two-drug regimens as the business transitions to the new portfolio. In Europe, overall dolutegravir sales growth was flat at both AER and CER with growth in dolutegravir share offset by price erosion, and the timing of clawback payments. International grew strongly with overall dolutegravir sales growth of 37% AER, 38% CER, driven by Tivicay and Triumeq. Oncology Sales of Zejula, were £99 million in the period from the date of acquisition, comprising £59 million in the US and £40 million in Europe. Immuno-inflammation Sales of Benlysta in the six months were up 27% AER, 21% CER to £271 million, including sales of the sub-cutaneous formulation. In the US, Benlysta grew 24% AER, 18% CER to £237 million. Established Pharmaceuticals Sales of Established Pharmaceuticals in the six months were £4,380 million, down 6% AER, 7% CER. Established Respiratory products declined 6% AER, 8% CER to £1,996 million, with the decline in Seretide/Advair partially offset by higher sales of Ventolin and allergy products. In the US, a generic version of Advair was launched in February, resulting in a 43% AER, 45% CER decline in the six months. In Europe, Seretide sales were down 17% AER, 17% CER to £262 million, reflecting continued competition from generic products and the transition of the Respiratory portfolio to newer products. In International, sales of Seretide grew 1% AER, 2% CER. Globally, Ventolin grew by 37% AER, 34% CER driven by the strong uptake of an authorised generic version in the US. The remainder of the Established Pharmaceuticals portfolio declined 5% AER, 5% CER broadly in line with the underlying mid single-digit decline expected of this portfolio. |
